Fachbereich Veterinärmedizin



    Moxifloxacin is not Anti-inflammatory in Experimental Pneumococcal Pneumonia (2015)

    Zeitschriftenartikel / wissenschaftlicher Beitrag
    Müller-Redetzky, H C
    Wienhold, S M
    Berg, J
    Hocke, A C
    Hippenstiel, S
    Hellwig, K
    Gutbier, B
    Opitz, B
    Neudecker, J
    Rückert, J
    Gruber, A D (WE 12)
    Kershaw, O (WE 12)
    Mayer, K
    Suttorp, N
    Witzenrath, M
    The Journal of antimicrobial chemotherapy; 70(3) — S. 830–840
    ISSN: 0305-7453
    DOI: 10.1093/jac/dku446
    Pubmed: 25406299
    Institut für Tierpathologie

    Robert-von-Ostertag-Str. 15
    Gebäude 12
    14163 Berlin
    Tel.+49 30 838 62450 Fax.+49 30 838 62522

    Abstract / Zusammenfassung

    Anti-inflammatory functions of antibiotics may counteract deleterious hyperinflammation in pneumonia. Moxifloxacin reportedly exhibits immunomodulatory properties, but experimental evidence in pneumonia is lacking. Therefore, we investigated moxifloxacin in comparison with ampicillin regarding pneumonia-associated pulmonary and systemic inflammation and lung injury.

    Ex vivo infected human lung tissue and mice with pneumococcal pneumonia were examined regarding local inflammatory response and bacterial growth. In vivo, clinical course of the disease, leucocyte dynamics, pulmonary vascular permeability, lung pathology and systemic inflammation were investigated. In addition, transcellular electrical resistance of thrombin-stimulated endothelial cell monolayers was quantified.

    Moxifloxacin reduced cytokine production in TNF-α-stimulated, but not in pneumococci-infected, human lung tissue. In vivo, moxifloxacin treatment resulted in reduced bacterial load as compared with ampicillin, whereas inflammatory parameters and lung pathology were not different. Moxifloxacin-treated mice developed less pulmonary vascular permeability during pneumonia, but neither combination therapy with moxifloxacin and ampicillin in vivo nor examination of endothelial monolayer integrity in vitro supported direct barrier-stabilizing effects of moxifloxacin.

    The current experimental data do not support the hypothesis that moxifloxacin exhibits potent anti-inflammatory properties in pneumococcal pneumonia.